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Abstract Inherited methylation disorders are a group of rarely
reported, probably largely underdiagnosed disorders affecting
transmethylation processes in the metabolic pathway between
methionine and homocysteine. These are methionine
adenosyltransferase I/III, glycine N-methyltransferase, S-
adenosylhomocysteine hydrolase and adenosine kinase defi-
ciencies. This paper provides the first consensus recommenda-
tions for the diagnosis and management of methylation disor-
ders. Following search of the literature and evaluation
according to the SIGN-methodology of all reported patients
with methylation defects, graded recommendations are provid-
ed in a structured way comprising diagnosis (clinical presenta-
tion, biochemical abnormalities, differential diagnosis, new-
born screening, prenatal diagnosis), therapy and follow-up.
Methylation disorders predominantly affect the liver, central
nervous system and muscles, but clinical presentation can vary
considerably between and within disorders. Although isolated
hypermethioninemia is the biochemical hallmark of this group
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of disorders, it is not always present, especially in early infancy.
Plasma S-adenosylmethionine and S-adenosylhomocysteine
are key metabolites for the biochemical clarification of isolated
hypermethioninemia. Mild hyperhomocysteinemia can be
present in all methylation disorders. Methylation disorders do
not qualify as primary targets of newborn screening. A low-
methionine diet can be beneficial in patients with methionine
adenosyltransferase I/III deficiency if plasma methionine con-
centrations exceed 800 μmol/L. There is some evidence that
this diet may also be beneficial in patients with S-
adenosylhomocysteine hydrolase and adenosine kinase defi-
ciencies. S-adenosylmethionine supplementation may be use-
ful in patients with methionine adenosyltransferase I/III defi-
ciency. Recommendations given in this article are based on
general principles and in practice should be adjusted individu-
ally according to patient’s age, severity of the disease, clinical
and laboratory findings.
Abbreviations
ADK Adenosine kinase
AdoHcy S-adenosylhomocysteine
AdoMet S-adenosylmethionine
CBS Cystathionine beta-synthase
CK Creatine kinase
GNMT Glycine N-methyltransferase
MAT Methionine adenosyltransferase
MRI Magnetic resonance imaging
SAHH S-adenosylhomocysteine hydrolase
tHcy Total homocysteine
Introduction
Inherited methylation disorders are a group of disorders affect-
ing the transmethylation processes in the metabolic pathway
between methionine and homocysteine (Fig. 1) .
Transmethylation is the transfer of a methyl group from methi-
onine via S-adenosylmethionine (AdoMet), which is the methyl
group donor in humans, to numerous acceptors. The large group
of methyl group acceptors includes important molecules such as
DNA, RNA, lipids, proteins and amino acids, neurotransmitters
and guanidinoacetate (Clarke and Banfield 2001). Methyl group
transfer is mediated by numerous different methyltransferases.
Katz and co-workers (Katz et al 2003) concluded from bioinfor-
matic analysis of various genomes, including that of humans,
that class-1 AdoMet-dependent methyltransferases correspond
to about 0.6 to 1.6 % of all open reading frames in analysed
genomes. This would point to about 300 AdoMet-dependent
methyltransferases in humans. The fact that transmethylation,
together with the process of remethylation of homocysteine to
methionine, i.e. the methionine cycle, occurs in almost all mam-
malian tissues and cells, also reflects its significance for normal
cellular hemostasis (Mudd et al 2001a; Finkelstein 2006;
Brosnan and Brosnan 2006; Blom et al 2006).
Methylation reactions are influenced by changes in the con-
centrations of AdoMet and S-adenosylhomocysteine
(AdoHcy), which may be reflected by their ratio (the so-
called methylation index). Since these are directly affected in
inherited methylation disorders, it is easily understandable that
the pathogenetic mechanisms of these disorders are complex,
still poorly understood and that many organs and body func-
tions may be affected. Therefore, inherited methylation disor-
ders should be included in the differential diagnosis of many
signs and symptoms, particularly concerning neurological,
muscle and liver function. A main aim of the BEuropean net-
work and registry for homocystinurias and methylation defects
(E-HOD)^ project is to provide recommendations for diagnosis
and treatment for this rare group of disorders. Since most phy-
sicians will not have any experience with methylation disor-
ders, they are probably largely underdiagnosed. In addition
there is a lack of validated and uniform therapeutic strategies
and follow-up approaches.
This paper deals with four inherited enzymopathies. Three
of these directly affect the reactions in the methionine path-
way. The first is the conversion of methionine to AdoMet,
catalyzed by methionine adenosyltransferase (MAT; E.C.
2.5.1.6). MAT has three isoforms. MAT I and MAT III are
liver specific, while MAT II is present mainly in fetal liver
and extrahepatic tissues. Both MAT I (a tetramer) and MAT
III (a dimer) are coded by the MAT1A gene, while MAT II is
coded by the MAT2A gene. Human disease can be caused by
mutations in theMAT1A gene, resulting inMAT I/III deficien-
cy (also called Mudd’s disease).1 To our knowledge, MAT II
deficiency has not been described as a human disease.
Individuals with a mutation in one of their MAT2A alleles
may be predisposed to thoracic aortic aneurysms (Guo et al
2015). The second enzyme is glycine N-methyltransferase
(GNMT; E.C. 2.1.1.20) which transfers a methyl group to
glycine producing sarcosine. GNMT deficiency causes eleva-
tion of AdoMet, as demonstrated both in humans and knock-
out mice (Mudd et al 2001b; Augoustides-Savvopoulou et al
2003; Rakic et al 2015; Barić et al 2016; Luka et al 2006). This
is the only methyltransferase deficiency which is known to
cause elevation of AdoMet, and therefore the only methyl-
transferase deficiency included in this article. GNMT is abun-
dantly expressed in the liver and regulates the degradation of
excess methyl groups, and is therefore a main regulator of
methionine metabolism (Yeo and Wagner 1994). The third
enzyme, S-adenosylhomocysteine hydrolase (SAHH; E.C.
3.3.1.1), is a homotetrameric enzyme, which converts S-
1 MAT I/III deficiency is also referred to as Mudd’s disease in recognition
of the late Harvey Mudd’s contribution to the knowledge of
hypermethioninemias in general and specifically to his efforts in produc-
ing the key review manuscript (Chien et al 2015) only a couple of weeks
before he passed away.
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adenosylhomocysteine to homocysteine and adenosine.
Adenosine kinase (ADK; E.C.2.7.1.20) is not a direct part of
the transmethylation process. It catalyzes the phosphorylation
of adenosine to adenosine monophosphate and its deficiency
causes the accumulation of adenosine, which subsequently
leads to elevation of AdoHcy and AdoMet thus disrupting
the methionine cycle and affecting the methylation processes.
Therefore, ADK deficiency results in a disorder of methyla-
tion and is thus included in this guideline.
Methods
Producing recommendations for diagnosis and treatment of the
methylation disorders was one of the aims of the E-HOD pro-
ject. To assure optimal expertise, experts within the E-HOD
network and authors of publications related to patients with
inherited methylation disorders have been invited to participate
in this work. Standard systematic literature searches and eval-
uations of the quality of evidence for guidelines/
recommendations production were performed according to
the SIGN methodology (for details see Supplementary
material). Due to the extreme rarity of most disorders we had
to simplify this approach. Thorough evaluation of all published
patients was complemented by the analysis of individual and
sporadic unpublished data (see Supplementary material for
more details).
Methylationdisordershavebeenvery rarely reported, either as
case reports or case series.We are aware of a total of five patients
withGNMTdeficiency, four reported in extenso in three publica-
tions (Mudd et al 2001b; Augoustides-Savvopoulou et al 2003;
Barić et al 2016), nine patientswithSAHHdeficiency reported in
seven publications in detail (Barić et al 2004, 2005; Buist et al
2006; Grubbs et al 2010; Honzík et al 2012; Strauss et al 2015;
Stender et al 2015) and 21 patients with ADK deficiency, 20 of
them reported in four articles in extenso (Bjursell et al 2011;
Labrune et al 1990; Staufner et al 2016a, b).Very recently, almost
all knownpatientswithMAT I/III deficiency (in total 64patients)
were extensively described (Chien et al 2015).
Methionine adenosyltransferase I/III deficiency
Diagnosis
Selective screening
Clinical presentation Patients may present with
neurodevelopmental problems and/or malodorous breath but
most patients have been detected in newborn screening
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Fig. 1 Methionine metabolism. AdoMet, S-adenosylmethionine;
AdoHcy, S-adenosylhomocysteine; THF, tetrahydrofolate; 5-MTHF, 5-
methyltetrahydrofolate; AMP, adenosine monophosphate. The
following enzymes are in circles: MAT, methionine adenosyltransferase
(E.C.2.5.1.6); GNMT, glycine N-methyltransferase (E.C.2.1.1.20); MTs,
a variety of AdoMet-dependent methyltransferases; SAHH, AdoHcy
hydrolase (E.C.3.3.1.1); CBS, cystathionine β-synthase (E.C.4.2.1.22);
MS, methionine synthase (5-MTHF-homocysteine methyltransferase)
(E.C.2.1.1.13); BHMT, betaine-homocysteine methyltransferase
(E.C.2.1.1.5); MTHFR, methylenetetrahydrofolate reductase
(E.C.1.5.1.20); ADK, adenosine kinase (E.C.2.7.1.20)
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programs (see also below). In the recent review describingmost
known patients withMAT I/III deficiency, 58 out of 64 patients
were ascertained by high methionine levels in newborn screen-
ing for CBS deficiency or via family members, and the remain-
ing were diagnosed via selective screening (Chien et al 2015).
About half of the patients with autosomal recessive MAT1A
mutations have developed neurological symptoms later in life, so
MAT I/III deficiency cannot be considered to be a benign genetic
disorder (Chien et al 2015). The reported symptoms, which
should accordingly be included in the differential diagnosis,were
mostly neurological such as subnormal psychomotor develop-
ment or intelligence, tremor, dystonia, dysmetria, severe head-
aches, nystagmus, dysdiadochokinesis, increased tendon re-
flexes, language difficulties and learning disabilities (Surtees
et al 1991; Chamberlin et al 2000; Mudd et al 1995, 2001a). In
addition, hypermethioninemia can be associatedwith an unusual
breathodour, presumablydue to formationofdimethylsulfidevia
transamination of methionine (Gahl et al 1988). Neurological
abnormalities have occurred particularly in patients with plasma
methionineconcentrationsabove800μmol/L,whereas theyhave
been rare in subjects with lower levels (Chien et al 2015).
Althoughthemajorityofpatientshavenormalbrainimages,some
brain imaging findings, in particular when associatedwith attrib-
utable clinical signs and symptoms or hypermethioninemia,
should also suggest MAT I/III deficiency. Typical changes are
demyelinationwithoedemaof subcortical anddeepwhitematter,
more pronounced in the dorsal brain stemand resulting in separa-
tion of myelin layers—the so-called vacuolating myelinopathy
(Chamberlin et al 1996; Tada et al 2004; Braverman et al 2005).
Grey matter and basal ganglia involvement has also been de-
scribed (Chamberlin et al 2000).
MAT I/III is a liver specific enzyme and liver histology was
studied in a fewMAT I/III-deficient patients. Light microscopy
was usually normal, but electron microscopy showed some
abnormalities, including mitochondria of abnormal shape or
breaks in their outer membranes and increased smooth and
decreased rough endoplasmic reticulum. Increased pericellular
collagen fibres were present in the space of Disse. Liver func-
tion tests in patients have been normal so far (Chien et al 2015)
although development of liver dysfunction in the long term
remains a theoretical possibility.
Biochemical abnormalitiesMAT I/III deficiency is the most
common cause of persistent isolated hypermethioninaemia.
Statement #1. Grade of recommendation C
MAT I/III deficiency should be suspected in all persons with
unexplained hypermethioninemia.
Statement #2. Grade of recommendation D
In persons with unexplained neurological signs and symp-
toms, disorders of methylation should be investigated at least
by analysis of plasma amino acids.
Differential diagnosis
Hypermethioninemia is often the first finding leading to sus-
picion of MAT I/III deficiency. Firstly, hypermethioninemia
due to CBS deficiency is excluded by measuring total homo-
cysteine (tHcy). If tHcy is normal or only slightly increased,
sequencing the MAT1A gene is the direct way to diagnosis.
MAT I/III is only expressed in liver, making enzymatic diag-
nostics impractical.
Other defects in methylation can be excluded by determin-
ing plasma AdoMet and AdoHcy which are elevated in other
methylation disorders (GNMT, SAHH, ADK deficiency) and
also in CBS deficiency. Patients with MAT I/III deficiency
usually have normal AdoMet and AdoHcy levels in plasma.
It may be confusing that AdoMet can be higher in the first
months of life, perhaps due to incomplete decline of MAT II
expression in the liver after birth. Measurement of AdoMet
and AdoHcy is only available in specialized centres.
A number of genetic causes of hypermethioninemia other
than those covered in these guidelines include heterozygosity
for MAT I/III deficiency and several inherited diseases affect-
ing liver function, including citrin deficiency, galactosemia
and tyrosinemia type I. Furthermore several non-genetic con-
ditions such as liver disorders or consumption of high methi-
onine containing infant formula and even prematurity can
cause hypermethioninemia. Thus exclusion of these causes
is essential in the diagnostic process.
Statement #3. Grade of recommendation D
Isolated hypermethioninemia should be followed up by mea-
surement of tHcy in plasma and if this is normal or slightly to
moderately elevated, plasma AdoMet and AdoHcy should be
measured.
Statement #4. Grade of recommendation C
Sequencing the MAT1A gene is recommended to confirm the
diagnosis of MAT I/III deficiency.
Newborn screening
In several countries methionine is used as a marker in new-
born screening to detect patients with homocystinuria due to
CBS deficiency (Mudd 2011), although the sensitivity and the
specificity for detecting CBS deficiency is poor, in particular
for B6-responsive CBS deficient patients (Huemer et al 2015).
Themedian dried blood spot concentrations ofmethionine in
143 MAT I/III-deficient individuals (including carriers) in the
BRegion 4 Stork (R4S) Collaborative Project^ database was
103 μmol/L compared to 20 μmol/L in healthy neonates
(McHugh et al 2011). A target cut-off value for methionine to
differentiate between the 99th centile in healthy newborns and
the 5th centile in confirmed true positive cases is in the range of
39 to 50 μmol/L (Huemer et al 2015). The number of patients
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with MAT I/III deficiency missed in newborn screening is not
known. Taken together, clinical and laboratory data are insuffi-
cient to develop recommendations on newborn screening for
MAT I/III deficiency (Huemer et al 2015).
Once a newborn with elevation of methionine is detected,
the next step in clinical assessment is the determination of
plasma tHcy, optimally by a second tier test using the original
dried blood spot (Turgeon et al 2010), although only very few
labs offer this assay. A common cause of elevated methionine
in newborn screening is the autosomal dominant form of
hypermethioninemia due to monoallelic mutations of MAT1A
(Chamberlin et al 1997). The most often reported dominant
mutation is c.791G >A (p.R264H) (Chien et al 2005; Martins
et al 2012; Couce et al 2013) but otherMAT1A mutations may
also cause dominant hypermethioninemia (Fernandez-Irigoyen
et al 2010). Blood methionine measurements in parents can
help to identify dominant hypermethioninemia although some-
times this may only be slightly elevated. Strong evidence indi-
cates that heterozygotes, in particular c.791G >A (p.R264H)
heterozygotes will be clinically unaffected (Couce et al 2013;
Chadwick et al 2014). See further under ‘differential diagnosis’
above. A baby of a mother with severe hypermethioninemia
may show transiently elevated methionine levels.
Statement #5. Grade of recommendation D
Most patients with MAT I/III deficiency have been detected
bynewborn screening.Due topotentiallyharmful consequences
of MAT I/III deficiency and relatively effective therapeutic op-
tions, neonatal screening for this disease may ultimately be jus-
tified.However,more clinical and laboratorydata are required to
make a firm recommendation to initiate newborn screening.
Statement #6. Grade of recommendation D
The most common cause for hypermethioninemia detected by
newborn screening is a dominant form of hyperme-
thioninemia due to heterozygosity for mutations in MAT1A.
This condition is considered benign.
Prenatal diagnosis
Prenatal diagnosis can be made using MAT1A gene analysis.
Enzyme assay in amniocytes or chorionic villi, as well as
measurement of metabolites in amniotic fluid, have not been
tested. The necessity for prenatal diagnosis should be carefully
considered before planning the procedure, since a substantial
number of patients with MAT I/III deficiency seem to be
asymptomatic, and since in the remaining patients the disease
is often treatable.
Statement #7. Grade of recommendation D
Prenatal testing in this disease is feasible via MAT1A gene
analysis.Prior to testing, it is essential that the indexcasehasbeen
confirmed genetically, and that the carrier status of the parents is
confirmed bymutation analysis. The necessity for prenatal diag-
nosis requires thoughtful discussion as a substantial number of
patientswithMATI/III deficiency seemtobeasymptomatic, and
since in the remaining patients the disease is often treatable.
Therapy
Theoretically, there are two therapeutic options: methionine
restriction and oral administration of AdoMet.
As described above, neurological abnormalities have tended
to occur in patients with plasma methionine concentrations
above 800 μmol/L, whereas they have been rare in subjects
with lower levels (Chien et al 2015). In some patients the use
of a methionine restricted diet seemed to be clinically beneficial
(Chien et al 2015). Therefore, if the mean methionine level is
above 800 μmol/L, dietary methionine restriction should be
considered, even in asymptomatic individuals, aiming at me-
thionine concentrations around 500 to 600 μmol/L (Chien et al
2015). A more rigid methionine restricted diet is difficult to
comply to and it does not seem to be clinically beneficial.
Theoretically, lowering methionine concentrations below
500 μmol/L may further limit the flux through MAT I/III, if
some residual MAT I/III activity remains, which would further
decrease the availability of AdoMet (Mudd 2011).
In all patients, possible development of central nervous
system signs and symptoms should be kept in mind and reg-
ular neurological and cognitive testing should be performed. If
indicated, brain MRI should be done. Symptomatic patients
should be treated with a methionine restricted diet if the me-
thionine level is above 600 μmol/L, again aiming at methio-
nine levels around 500 to 600 μmol/L.
AdoMet supplementation may be indicated if clinical signs
and symptoms develop while on methionine restriction. The
most effective oral dose of AdoMet is unknown. Doses be-
tween 400 to 1600 mg/day have been used in various condi-
tions and AdoMet seems to be well tolerated. The available
evidence suggests that AdoMet supplementation may lead to
normalization of brain imaging changes (Chien et al 2015).
Statement #8. Grade of recommendation D
If plasma methionine concentrations are above 800 μmol/L, a
methionine restricted diet is recommended, with the aim to
maintain methionine levels around 500–600 μmol/L, even in
asymptomatic individuals.
Symptomatic patients with methionine levels between 600
and 800 umol/L should aim for methionine levels around
500–600 μmol/L.
If the mean plasma methionine is below 500–600 μmol/L,
treatment seems not to be indicated.
Statement #9. Grade of recommendation D
Besides methionine restriction AdoMet supplementation may
be considered as a treatment option.
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Statement #10. Grade of recommendation C
If clinical signs or symptoms develop while on methionine
restriction, supplementing with AdoMet should be
considered.
Follow-up
Monitoring
Methionine should be measured at regular intervals, the first
years of life around every 2 to 3 months, and later in life every
6 to 12 months. Exact timing for monitoring of methionine
concentrations depends on each patient’s individual values
and the risk to have concentrations above 800 μmol/L.
In patients on a methionine restricted diet, regular assess-
ments of protein status, amino acids and AdoMet are indicated.
About half of the patients with autosomal recessiveMAT1A
mutations have developed central nervous system complica-
tions (Chien et al 2015). Therefore, neurological and cognitive
testing should be performed regularly in all patients. We sug-
gest that neurological testing should take place maybe once
every 2 to 3 months in infants, and every 6 to 12 later in life. If
indicated, brain MRI should be performed.
Statement #11. Grade of recommendation C-D
Methionine should be measured at regular intervals, the first
years of life around every 2 to 3 months, and later in life every
6 to 12 months. Regular monitoring of methionine concentra-
tions also depends on each patient’s individual values and
their potential for concentrations above 800 μmol/L.
Statement #12. Grade of recommendation D
Neurological and cognitive testing should be performed reg-
ularly in all patients. We suggest that neurological testing
should take place once every 2 to 3 months in infants, and
every 6 to 12 months later in life. If indicated, brain MRI
should be performed.
Complications
Central nervous system complications are described in the
section on clinical presentation.
Glycine N-methyltransferase deficiency
Diagnosis
Selective screening
Clinical presentation GNMT deficiency in humans is an au-
tosomal recessive defect which was discovered 15 years ago
(Mudd et al 2001b). However, to date, only five individuals
from four families have been diagnosed, four of whom have
been described in detail (Mudd et al 2001b; Augoustides-
Savvopoulou et al 2003; Barić et al 2016) and one in an abstract
(Rakic et al 2015). The fact that three of the individuals 18, 15
and 17 years after diagnosis remain clinically well (personal
communications R. Cerone and P. Augoustides-Savvopoulou
respectively) favours the view that this is a benign disorder in
humans. However, taking into account observations that highly
elevated plasma methionine itself is a risk factor for develop-
ment of neurological signs and symptoms (see MAT I/III defi-
ciency above), and that individuals with GNMT deficiency can
have plasma methionine concentrations in the range which has
been shown to be associated with clinical problems, signs and
symptoms related to high methionine can be anticipated
(Braverman et al 2005; Mudd 2011).
Based on the findings in the five diagnosed individuals,
characteristics of GNMT deficiency are mild to moderate fluc-
tuating elevations of serum aminotransferases and lack of clin-
ical symptoms—the only clinical sign present in two individ-
uals (siblings) being mild hepatomegaly. Presenting symp-
toms in three individuals were upper respiratory tract infec-
tion, failure to thrive and febrile convulsions, respectively. It is
unclear whether these symptoms were related to GNMT defi-
ciency. Of note is that aminotransferase levels within the ref-
erence range can occur (as observed in two unrelated individ-
uals) and does not exclude the diagnosis. Liver biopsy was
performed in two of the five individuals—one with hepato-
megaly had mild centrilobular fibrosis with eosinophilic infil-
tration and one without hepatomegaly had essentially normal
findings, showing only mild hydropic degeneration of a few
hepatic cells. Liver ultrasound in this individual showed in-
creased echogenicity of periportal spaces only. In all five in-
dividuals the unexplained hyperaminotransferasemia (i.e. not
attributable to conventional causes of liver disease) triggered
the metabolic workup which led to the correct diagnosis.
Biochemical abnormalities Assays of plasma amino acids
revealed isolated marked hypermethioninemia ranging from
400 to 1247 μmol/L (ref. range 13–45). Further investigation
revealed remarkably high levels of plasma AdoMet in all five
individuals (1149–2840 μmol/L, ref. range 73–109), with plas-
ma AdoHcy levels within the normal range (21–72 μmol/L, ref.
range 15–45). Plasma sarcosine (N-methylglycine) was mea-
sured in three patients (Mudd et al 2001b; Augoustides-
Savvopoulou et al 2003) andwaswell within the reference range
(1.4-2.1 μmol/L, ref. range 0.6-2.7). Hypermethioninemia ac-
companied by very high levels of plasma AdoMet in the pres-
ence of normal plasma AdoHcy and sarcosine are considered
diagnostic hallmarks of GNMT deficiency. Interestingly, in one
child AdoMet levels in whole blood were in the upper normal
range, although with an increased AdoMet/AdoHcy ratio (Barić
et al 2016). However, in plasma, AdoMet was highly elevated—
3348 nmol/L (reference range 71–118 nmol/L), while AdoHcy
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was 63 nmol/L (reference range 9.3–14.1 nmol/L). A plausible
explanation for increasedAdoHcy in this individual could be the
extremely high plasma AdoMet which may have caused a sec-
ondary increase of AdoHcy via non-enzymatic or artefactual
decay of AdoMet. In fact, AdoMet is an unstable compound
and can break down to AdoHcy due to inappropriate handling
or storage, particularly if the sample is not properly acidified.
This also shows that plasma is the sample of choice for assaying
AdoMet and AdoHcy. This individual also differed in the fact
that mild elevations of plasma tHcy levels (21.4-28.3 μmol/L,
ref. range 5–12) were found which can be explained by the
inhibitory effect of high methionine levels on betaine-homocys-
teine-methyltransferase, N5-methyltetrahydrofolate–homocys-
teine methyltransferase and cystathionine gamma-lyase activity
(Barić et al 2016). The diagnosis in all five individuals was
confirmed by GNMT mutation analysis. Three individuals, in-
cluding the two siblings, were compound heterozygotes for two
missense mutations c.1481 T > C (Leu49Pro), c.3715C >A
(His176Asn) and c.529C > A (His177Asn), c.431C > T
(Ala144Val), respectively (Luka et al 2002; Rakic et al 2015).
The His176Asn and His177Asn mutations are in fact the same
variant, albeit reported differently by molecular clinical labora-
tories. Two individuals were homozygous, one for the
c.3415A > G (Asn140Ser) mutation (Augoustides-
Savvopoulou et al 2003) and the other for the c.296G >A
(Arg99His) mutation (Barić et al 2016). Expression studies in
three individuals revealed decreased activity for the mutations as
follows: Leu49Pro 10 %, His176Asn 75 %, and Asn140Ser
0.5 % of wild type activity (Luka and Wagner 2003) and in
one (Arg99His) minimal activity (Barić et al 2016).
Predictions of in vivo enzyme activities on the basis of activities
found in expression studies can be difficult. Kinetic factors and
protein conformational changes as possible causes of impaired
enzyme function have been studied for mutations Leu49Pro,
His176Asn and Asn140Ser, and were discussed in detail
(Luka and Wagner 2003).
Thus the initial approach to diagnosis of GNMTdeficiency is
clinical suspicion of asymptomatic individuals with permanent
or intermittent elevation of aminotransferases (with or without
hepatomegaly) followed bymeasurement of plasma amino acids
and tHcy. The presence of marked isolated hypermethioninemia
should be followed up by measurement of plasma AdoMet and
AdoHcy concentrations (including the AdoMet/AdoHcy ratio)
and where possible sarcosine, as normal levels of AdoHcy and
sarcosine in the presence of greatly increased AdoMet levels are
a strong indicator of GNMTdeficiency (Mudd 2011). Diagnosis
of GNMT deficiency should be confirmed by GNMT mutation
analysis and, when necessary, expression studies. Enzyme assay
is possible but requires a liver biopsy.
Statement #13. Grade of recommendation C
Clinical characteristics of GNMT deficiency are mild to moder-
ate fluctuating elevations of aminotransferases (with or without
hepatomegaly) and lack of symptoms. Aminotransferase levels
in the reference range can occur and do not exclude the
diagnosis.
Statement #14. Grade of recommendation D
The cornerstone of diagnosis is awareness of GNMT deficien-
cy and increased clinical suspicion of asymptomatic individ-
uals with unexplained elevations of aminotransferases. The
initial laboratory approach is measurement of plasma amino
acids and tHcy. The presence of persistent marked isolated
hypermethioninemia should be followed by assays of plasma
AdoMet and AdoHcy concentrations paying attention to the
AdoMet/AdoHcy ratio and if possible plasma sarcosine. The
diagnosis should be confirmed by GNMT mutation analysis
and where necessary, expression studies.
Differential diagnosis
Differential diagnosis should include other causes of
hypermethioninemia, genetic and acquired. In contrast to
GNMT deficiency most of these disorders are characterized
by a range of clinical findings. Careful clinical evaluation
combined with key laboratory tests should facilitate their ex-
clusion (see flow chart, Fig. 2).
Newborn screening
At the present time, GNMT deficiency does not fulfil the criteria
for inclusion in newborn screening programs (Wilson and
Jungner 1968; Andermann et al 2008). Furthermore it is un-
known whether methionine levels are increased in newborns
with GNMT deficiency although the normal blood spot methi-
onine level (19.5μmol/l, ref. values 15–47) obtained at newborn
screening in one patient (Rakic et al 2015) may indicate that
hypermethioninemia is not present from birth. AdoMet cannot
be used as a newborn screening analyte due to its chemical
instability.
Statement #15. Grade of recommendation D
Based on the present knowledge, GNMT deficiency does not
fulfil the criteria for inclusion in newborn screening programs.
Prenatal diagnosis
Prenatal diagnosis of GNMTdeficiency is possible (with iden-
tification of GNMT mutations of the index case) but based on
the clinical data of the five diagnosed patients, is irrelevant.
Statement #16. Grade of recommendation D
To date, GNMT deficiency in humans is an apparently benign
disorder, thus prenatal diagnosis although possible is not
recommended.
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Therapy
The necessity for treatment of this asymptomatic seemingly
benign disorder is presently questionable, careful follow-up
being the main parameter for optimal care. Theoretically, cor-
rection of the biochemical abnormality to suppress possible
adverse effects would be the therapeutic target, and as evi-
denced in the first proven individual with GNMT deficiency
a low methionine diet (300 mg/day) can correct the biochem-
ical abnormalities (Mudd et al 2001b). However, subjecting
asymptomatic individuals to a methionine restricted diet (in
infancy 15-20 mg/kg/day) is questionable and has potentially
deleterious consequences, e.g. methionine deficiency and re-
lated consequences of protein malnutrition and effects on the
methionine pathway (Mudd 2011; Barić et al 2016). On the
other hand, central nervous system complications
(vacuolating myelinopathy) have been described in patients
with high levels of methionine (>1000 μmol/L), independent
of underlying etiology (Braverman et al 2005; Mudd 2011).
To decrease this risk it has been proposed that methionine
restriction should be implemented when levels exceed
800 μmol/L (Chien et al 2015), but this cut-off is arbitrary.
The aim of the diet should be to maintain methionine levels
around 500–600 μmol/L. Recent findings suggest that a po-
tential therapeutic approach may be nicotinamide, which is a
substrate for alternative AdoMet dependent methyltransfer-
ases. This amide derivative of nicotinic acid has been shown
to prevent steatosis and liver fibrosis and to lower the AdoMet
levels inGnmt k/o mice. In addition, it prevented DNA hyper-
methylation and expression of a variety of genes involved in
various deleterious processes, e.g. oxidative stress (Varela-
Rey et al 2010). However, all of these pathological changes
which can be prevented in mice have never been reported in
humans with GNMT deficiency.
Follow-up
Monitoring
Clinical monitoring Although GNMT deficiency in humans
seems to be a benign disorder this does not appear to be the
case in k/o mouse models of GNMT deficiency. The initial
findings in these mice confirmed the biochemical abnormali-
ties seen in humans as well as the importance of GNMT for
regulation of the AdoMet/AdoHcy ratio and cellular methyl-
ation activity (Luka et al 2006, 2009). Recently, elevated ami-
notransferases, chronic hepatitis (Liu et al 2007), liver
steatosis (Liao et al 2012; Zubiete-Franco et al 2015), athero-
sclerosis (Chen et al 2012), liver fibrosis and most importantly
hepatocellular carcinoma (Chen et al 1998; Avila et al 2000;
Tseng et al 2003; Martinez-Chantar et al 2008; Varela-Rey
et al 2009; Lu and Mato 2012), prostatic cancer (Song et al
2013; Chen et al 2014; Yen et al 2013) and pancreatic ductal
adenocarcinoma (Botezatu et al 2015) have been reported and
indicate that independent of its metabolic properties, GNMT is
also a regulator of cellular proliferation.
Physicians following patients with GNMT deficiency
should be aware that besides the liver, GNMT protein is
expressed in a number of tissues (prostate, exocrine tissue of
the pancreas, proximal kidney tubules, submaxillary glands,
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Fig. 2 Diagnostic flow-chart in
patients with
hypermethioninemia (extracted
from Barić and Fowler 2014 and
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intestinal mucosa, cortical neurons and Purkinje cells of the
brain) (Luka et al 2009) and that the increasing ongoing re-
search of its functional diversity may be of potential signifi-
cance for the prognosis and hence monitoring of these patients.
Biochemical monitoring As GNMT deficient patients can
have very high methionine levels which have been related to
central nervous system complications, monitoring of plasma
methionine levels is recommended.
Although none of the five patients with GNMT deficiency
show any apparent signs of clinical or biochemical deteriora-
tion, in view of the findings in Gnmt k/o mouse models (see
above), regular measurements of aminotransferases, synthetic
liver function (albumin, prothrombin time) and plasma methi-
onine are recommended. It may be advisable to include yearly
assessments of plasma alpha-fetoprotein levels as well as liver
ultrasound.
Statement #17. Grade of recommendation D
Clinicians should be aware of the potential central nervous
system complications of severe hypermethioninemia and thor-
oughly assess the patient, neurologically as well as by plasma
methionine monitoring, at intervals depending on age and
clinical course.
Statement #18. Grade of recommendation D
Due to the limited experience of GNMT deficiency in humans
and liver findings inGnmt k/o mice, GNMT deficient individ-
uals should be monitored on a regular basis with measure-
ments of aminotransferases, synthetic liver function, serum
alpha-fetoprotein and liver ultrasound in intervals depending
on age and clinical course.
Complications
To date, complications of GNMT deficiency in humans have
not been observed.
S-adenosylhomocysteine hydrolase deficiency
Diagnosis
Selective screening
The clinical suspicion of S-adenosylhomocysteine hydrolase
deficiency is guided by findings in ten reported patients from
six families (Barić et al 2004, 2005; Buist et al 2006; Ćuk et al
2007; Grubbs et al 2010; Honzík et al 2012; Strauss et al 2015;
Stender et al 2015). Two sibs presented severely with fetal
hydrops, insufficient liver synthetic function and muscular
hypotonia leading to respiratory failure and death in early
infancy. Both sisters had cerebellar and pontine hypoplasia,
hypoplastic corpus callosum and hypomyelination (Grubbs
et al 2010). Muscle disease with increased CK activity was
also present in all patients with a relatively milder phenotype.
In addition, they had various combinations of developmental
delay, behavioural disorders, microcephaly, myelination de-
lay, strabismus, coagulopathy and liver disease. Muscle his-
tology in several patients suggested dystrophic processes.
A novel, very recently reported dimension of the disease is
the development of hepatocellular carcinoma, which occurred
in a female patient at the age of 29 years and her brother, who
likely had SAHH deficiency (Stender et al 2015). SAHH de-
ficiency was diagnosed in the female post mortem by whole
exome sequencing. Her son, harbouring the same homozy-
gous missense mutation as his mother, was diagnosed with
SAHH deficiency at the age of 7 years. He was reported to
be asymptomatic, although he had mildly to moderately ele-
vated aminotransferases, decreased albumin and markedly el-
evated serum levels of methionine, AdoMet and AdoHcy. CK
activity was not reported.
Statement #19. Grade of recommendation C-D
SAHH deficiency should be suspected in patients with any
combination of myopathywithmarkedly increased CK activity,
being the most constant feature, followed by hypotonia, devel-
opmental delay, hypomyelination, behavioural problems, liver
disease (including hepatocellular carcinoma), coagulation dis-
orders, strabismus and fetal hydrops with brain abnormalities.
Statement #20. Grade of recommendation C
SAHH patients may also be asymptomatic.
Biochemical abnormalities include elevated aminotrans-
ferases and CK activities and variable coagulation abnormali-
ties. Repeatedly reported were: prolonged prothrombin time,
low fibrinogen, antithrombin III, protein S, factor II and partic-
ularly factor VII, and increased factor V. Specific abnormalities
pointing to the diagnosis are markedly elevated plasma
AdoMet and particularly elevated plasma AdoHcy with normal
or near normal tHcy. Plasma methionine can be normal in early
infancy, but after that period in untreated patients it is probably
constantly elevated. However, since hypermethioninemia is not
a constant finding, it is essential to measure AdoMet and
AdoHcy in all cases with clinical suspicion of the disorder. In
reported patients plasmaAdoMet was ∼18-50-fold elevated (up
to 5109 nmol/L, reference range 91 ± 28), while AdoHcy was
∼12-200-fold elevated (up to 8139 nmol/L, reference range 27
± 15). In early infancy these elevations can be less manifest.
Biallelic pathogenic mutations in the AHCY gene have been
found in all patients with SAHH deficiency.
Statement #21. Grade of recommendation C
In all cases with clinical suspicion of SAHH deficiency, plas-
ma AdoMet and AdoHcy should be measured because their
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marked elevations in combination with normal or near normal
tHcy are characteristic for the diagnosis. Plasma methionine
may be normal in early infancy, but consequently likely to be
constantly elevated in untreated patients. Diagnosis must be
confirmed by either enzyme assay (possible in red blood cells,
fibroblasts and liver) or by mutation analysis.
Differential diagnosis
Based on the multiorgan clinical presentation, SAHH defi-
ciency has a very wide differential diagnosis. Once
hypermethioninemia is found, further testing depends primar-
ily on the presence of liver disease, hyperhomocysteinemia
and other amino acid abnormalities. A similar constellation
of metabolic findings (elevated plasma methionine, AdoMet
and AdoHcy) has been reported only in ADK-deficient pa-
tients. However, in contrast to patients with SAHH deficiency,
these patients have a much milder elevation of AdoMet and
especially AdoHcy, with AdoMet levels being higher than
AdoHcy. In addition, CK activity is increased only in some
ADK-deficient patients, while in SAHH-deficient patients in-
creased CK activity is a constant finding with much higher
activity than in ADK deficiency (in SAHH deficiency almost
always more than fivefold and frequently much more).
Clinical presentation is also rather different in SAHH deficien-
cy and ADK deficiency (see related sections in this article).
For a related diagnostic algorithm see Fig. 2.
Newborn screening
Since SAHH deficiency seems to be partly treatable at least in
some cases and there are indications that early diagnosis im-
proves the outcome (Barić et al 2005; Strauss et al 2015), early
identification through newborn screening could be beneficial.
Currently, the only feasible way is screening for
hypermethioninemia, usually done to identify CBS deficien-
cy. Unfortunately, hypermethioninemia was present only in
two out of six patients with SAHH deficiency in whom data
on plasma methionine or dried blood spot methionine at the
time of newborn screening was available. In two of those six
patients newborn screening was performed. One of these pa-
tients had on day 3 a blood methionine level of 200 μmol/L,
using the Guthrie bacterial inhibition assay (Buist et al 2006),
while the other had a normal methionine level (20 μmol/L),
measured by tandem mass spectrometry (Strauss et al 2015).
In the remaining four patients in whom data on methionine at
the time of newborn screening was available, plasma methio-
nine was measured either because of SAHH deficiency in
family members, and was normal in three patients (Barić
et al 2005; I. Barić- personal communication), or because of
clinical indication. In the latter case it was elevated (273μmol/
L) on day 4 (Grubbs et al 2010). A related important issue is
the necessity for further diagnostic work-up following positive
screening. Since increased CK activity seems to be a constant
finding in SAHH deficiency, measurement of CK in dried
blood spots could be an option for newborn screening, as
has been used for newborn screening for Duchenne muscular
dystrophy (Zellweger and Antonik 1975; Orfanos and Naylor
1984).
Statement #22. Grade of recommendation D
Since early treatment has shown a positive effect in some
cases early identification through newborn screening may be
beneficial.
Statement #23. Grade of recommendation C
At present, there is no sensitive screening test available to
allow for newborn screening. Therefore, newborn screening
is presently not possible.
Prenatal diagnosis
The only established way is the AHCY gene analysis. This is
possible if the disease causing mutations are known and the
carrier status of the parents has been confirmed by mutation
analysis. Enzyme assay in amniocytes or chorionic villi, as
well as measurement of metabolites in amniotic fluid have
not been tested. The necessity for prenatal diagnosis requires
thoughtful discussion, one of the reasons being the clinical
variability of SAHH deficiency.
Statement #24. Grade of recommendation D
If the disease causing mutations are known, prenatal diagnosis
is possible by AHCY gene analysis.
Therapy
It seems that there are two main obstacles for the successful
aetiological therapy of SAHH deficiency. The first is its
multisystemic character and the second is the antenatal onset
of the disease in almost all patients, with possibly irreversible
consequences. Taking into account that normal biochemical
findings (at least CK) have never been reported even in
asymptomatic patients or in patients with late clinical onset,
it is possible that biochemical abnormalities are present in all
patients already in utero.
A low methionine diet can decrease and sometimes even
normalize plasma AdoMet and AdoHcy, which may have
positive effects on methylation and clinical and biochemical
abnormalities (Barić et al 2005; Honzík et al 2012; Strauss
et al 2015). It is probably justified to keep plasma methionine
close to or slightly below the lower normal limit (∼10μmol/L)
to ensure the maximal possible decrease of plasma AdoMet
and AdoHcy. For this purpose, patients have to be on a protein
restricted diet and supplementedwith amethionine-free amino
acid mixture. Subsequent close clinical and biochemical
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monitoring seemmandatory. Phosphatidylcholine supplemen-
tation has been proposed because of expected inhibition of
phosphatidylethanolamine methyltransferase by highly ele-
vated AdoHcy, which inhibits numerous methyltransferases
(Clarke and Banfield 2001). This enzyme is required for phos-
phatidylcholine and choline synthesis, which is important for
muscles, liver and myelin. Low plasma free choline and phos-
phatidylcholine before treatment in the first reported patient
with SAHH deficiency are consistent with the inhibition of
phosphatidylethanolamine methyltransferase by the 150-fold
elevation of plasma AdoHcy in that patient (Barić et al 2004),
and by a study showing that a 100-fold elevation of AdoHcy
decreases the activity of this methyltransferase by about 90 %
(Ghosh et al 1988).
Creatine supplementation has been derived from the as-
sumed inhibition of guanidinoacetate methyltransferase by
high AdoHcy and findings of elevated guanidinoacetate in
plasma or urine in some SAHH-deficient patients (Barić
et al 2004; Buist et al 2006). Both phosphatidylcholine and
creatine supplementation have been used in some patients,
although there is no evidence that this treatment, which has
been applied only in parallel with other therapeutic measures
(low protein/methionine diet), results in clinical improvement.
Due to the possible risk of glutathione depletion cysteine sup-
plementation may be useful, but there is no evidence that this
is really needed.
Recently, liver transplantation was successfully performed
in one girl at the age of 40 months (Strauss et al 2015). The
indication was insufficient success of a low methionine diet of
about 35 mg/kg/day (∼2 g protein/kg/day) together with cre-
atine and choline supplementation with aims to positively in-
fluence developmental delay and correct transmethylation ho-
meostasis. Open to speculation was whether a more restrictive
diet would have resulted in a better treatment outcome thus
alleviating the need for liver transplantation. During the 6-
month follow-up period, however, liver transplantation result-
ed in improvement of the AdoMet/AdoHcy ratio, normaliza-
tion of plasma methionine and AdoMet and acceleration of
head growth with promising gains in gross motor, language
and social skills. The recent report on hepatocellular carcino-
ma in an adult with SAHH-deficiency (Stender et al 2015)
provides an additional argument in favour of liver transplan-
tation in SAHH deficiency. Longer follow-up is needed for
better assessment of indications for and outcome of liver trans-
plantation in SAHH deficiency.
The treatment outcome probably depends a lot on the se-
verity of the disease. It is questionable whether even early
intervention could help in severe cases. In others, it is possible
that earlier initiation of treatment may improve the outcome.
This may be the case both for liver transplantation and a low-
methionine diet combined with supplementation of phospha-
tidylcholine and creatine. It seems that neurological, liver and
coagulation abnormalities can be influenced by treatment,
while the muscle disease seems as yet far less responsive or
even unresponsive.
Statement #25. Grade of recommendation C
A low methionine diet is recommended since it can decrease
and sometimes even normalize plasma AdoMet and AdoHcy,
which in turn can have a positive effect on methylation and
clinical and biochemical abnormalities. Methionine-free ami-
no acid mixture supplementation may be necessary.
Theoretically, phosphatidylcholine, creatine and cysteine sup-
plementation seem potentially beneficial, but there is no evi-
dence that this treatment results in clinical improvement.
Statement #26. Grade of recommendation C
Liver transplantation has resulted in clinical improvement as
well as improvement of the AdoMet/AdoHcy ratio and nor-
malization of plasma methionine, AdoMet and indices of in-
creased transmethylation in a single case. Longer follow-up is
needed for better assessment of the utility and indications for
liver transplantation in SAHH deficiency.
Follow-up
Monitoring
Clinically, regular careful evaluation of all body systems is
indicated, particularly of the nervous system, psychomotor de-
velopment, muscles, liver and coagulation. This includes imag-
ing studies, particularly regular liver imaging. Biochemically,
assessment of protein status, amino acids, AdoMet, AdoHcy,
liver function tests, alpha-fetoprotein, CK and coagulation tests
are needed. Follow-up intervals in infancy could be every 1–
3 months, or even more frequently if indicated, and later every
3 to 6 months depending on the clinical course. For patients
with liver transplants specific transplantation related follow-up
regimens need to be followed.
Statement #27. Grade of recommendation C-D
Careful clinical and biochemical monitoring is mandatory to
control both disease development and treatment to avoid their
complications. The following tests are indicated: protein sta-
tus, amino acids, AdoMet, AdoHcy, liver function tests, CK,
alpha-fetoprotein, coagulation tests, liver imaging, while
others depend on the clinical situation. Follow-up intervals
depend on age and clinical course.
Complications
Besides the usual clinical course, complications due to bleed-
ing diathesis, thromboembolic incidents and adaptation prob-
lems after birth due to hypotonia and respiratory insufficiency
(including feeding) can be expected. An episode of liver fail-
ure has been reported once, but it is hardly possible to assess
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whether this was a direct consequence of the disease or due to
another undefined factor. Based on occurrence in one patient
with a proven diagnosis and in her sib with probable SAHH
deficiency, hepatocellular carcinoma is a possible complica-
tion. Behaviour-related complications are probably to be ex-
pected more frequently than in the general population.
Adenosine kinase deficiency
Diagnosis
Selective screening
The clinical presentation of adenosine kinase deficiency
(ADK deficiency) is multisystemic including intellectual and
motor disability, muscular hypotonia, morphological abnor-
malities (especially frontal bossing), hepatopathy, epilepsy
and recurrent hypoglycaemia (often due to hyperinsulinism).
Initial symptoms are usually already evident within the neo-
natal period with severe or prolonged hyperbilirubinemia,
hypoglycaemia and muscular hypotonia (Bjursell et al 2011;
Labrune et al 1990; Staufner et al 2016a). Other signs and
symptoms reported were: cardiac defects, failure to thrive
and short stature, hypertelorism, strabismus, sparse hair, long
and triagonal face, slender hands and feet, distorted teeth,
megaloblastic anemia, retinal dystrophy and cholelithiasis.
ADK deficiency was described in 2011 (Bjursell et al 2011)
and to date, 20 patients have been published in the literature
(Bjursell et al 2011; Staufner et al 2016a; Labrune et al 1990—
initial diagnosis was suspected to be SAHH deficiency and the
correct diagnosis has been established recently). All known
patients have intellectual disability ranging from moderate to
very severe, frontal bossing and muscular hypotonia. Most pa-
tients develop seizures (70 %) with a median age of onset at
2 years and many have intractable epilepsy. Hepatopathy typ-
ically manifests during the neonatal period, is most prominent
during the first year of life and ameliorates in the further course.
It can be accompanied by severe coagulopathy mimicking
acute liver failure. There is chronic liver disease with steatosis
and 75 % were found to have liver fibrosis. Liver involvement
is a very typical finding in ADK deficiency, but liver disease is
not mandatory (Staufner et al 2016a). One patient has been
diagnosed with a malignant hepatic tumour at the age of
14 years, which has an atypical histopathological appearance
but most likely represents a hepatocellular carcinoma (C.
Staufner—personnal communication).
Brain MRI in ADK deficiency shows delayed but ultimate-
ly complete brain maturation, which includes temporarily de-
layed gyral patterning and myelination. There are mostly un-
specific white matter changes and potentially transient central
tegmental tract hyperintensity (Staufner et al 2016b).
Biochemical abnormalities depend on current liver im-
pairment. There can be elevated aminotransferases (ALAT,
ASAT), direct hyperbilirubinemia and coagulation abnormal-
ities (prolonged prothrombin time). Specific abnormalities are
elevated plasma methionine (up to 1100 μmol/L, however
methionine concentrations fluctuate and can be normal!), ele-
vations of plasma AdoMet and AdoHcy with normal or near
normal tHcy. In the reported patients, plasmaAdoMet was ∼2-
20-fold elevated (up to 2299 nmol/L), while AdoHcy was ∼5-
30-fold elevated (up to 438 nmol/L). Adenosine in dried blood
spots and urine is typically elevated, but can be normal. Two
patients had mild to moderate hyperammonemia in early in-
fancy (Staufner et al 2016a).
Clinical suspicion should be raised by the combination of
some or all of the clinical signs and symptoms of the disease
described above. To confirm the diagnosis, genetic analysis of
ADK is recommended. To our knowledge, enzyme assays are
not available.
Statement #28. Grade of recommendation C
In the case of clinical suspicion of ADK deficiency amino
acids, AdoMet, AdoHcy and tHcy in plasma, and adenosine
in urine and/or dried blood spots should be assessed. Normal
concentrations of methionine and/or adenosine are frequently
found and do not rule out the diagnosis. To confirm the
diagnosis genetic analysis of ADK is essential.
Differential diagnosis
ADK deficiency may mimic the biochemical pattern of
SAHH deficiency (high methionine, AdoMet and AdoHcy).
However, clinical features can guide the differentiation, for
example dysmorphism, neonatal hyperbilirubinemia and epi-
lepsy are frequent in ADK deficiency but not present in
SAHH deficiency. CK, AdoMet and especially AdoHcy are
generally much higher in SAHH deficiency compared to
ADK deficiency. Increased adenosine levels point to ADK
deficiency, but are not present in all cases.
Other inborn errors of metabolism with transient neonatal
cholestasis or hepatopathy are, e.g. mannose phosphate
isomerase-CDG (MPI-CDG, formerly called CDG Ib), citrin
deficiency, Niemann Pick disease type C, mitochondrial dis-
orders, peroxisomal disorders, neuronopathic Gaucher disease
and biliary acid synthesis disorders.
Newborn screening
So far, there is no sensitive marker that would allow newborn
screening for ADK deficiency. Hypermethioninemia was not a
consistent finding in newborn screening dried blood spots of
affected patients but elevated adenosine may be an option
(Staufner et al 2016a). Due to limited knowledge of the natural
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history and therapeutic options, newborn screening is not indi-
cated as yet.
Statement #29. Grade of recommendation D
At present, newborn screening is not justified due to limited
knowledge of the natural history and therapeutic options.
Prenatal diagnosis
Theoretically, genetic testing can be performed prenatally and
the presence of known mutations of the ADK gene can be
confirmed or ruled out. As yet, there is no experience of pre-
natal diagnosis in ADK deficiency.
Therapy
There is evidence for a positive effect of a lowmethionine diet
(reduction of the daily intake of methionine to 15–20 mg per
kg of body weight) in seven patients with ADK deficiency
from different centres (Labrune et al 1990; Staufner et al
2016a). Under dietary treatment the liver phenotype amelio-
rates clinically and biochemically, whereas a positive effect on
the neurological outcome has only been reported in a single
case. Decreased intake of methionine lowered the concentra-
tions of methionine, tHcy, AdoMet and AdoHcy in plasma
and adenosine in whole blood.
Diazoxide appears to be an effective treatment of recurrent
hypoglycaemia caused by hyperinsulinism in ADK deficiency
(Staufner et al 2016a).
Further therapeutic options yet to be explored are alterna-
tive degradation of adenosine via adenosine deaminase
(ADA), which is currently available as enzyme replacement
therapy for ADA-SCID patients, or caffeine treatment which
can antagonize central adenosine receptors.
Statement #30. Grade of recommendation C
A low methionine diet should be considered as a therapeutic
option. Diazoxide is recommended for recurrent
hypoglycaemia when it is due to hyperinsulinism.
Follow-up
Monitoring
Careful clinical evaluationwith regular follow-up visits depend-
ing on age and severity is recommended (intervals ranging from
1month to 1 year), including regular monitoring of psychomotor
development and neurological examination and regular liver im-
aging. Since epilepsy is often present in ADK deficiency, regular
electroencephalography is recommended. In one patient retinal
dystrophywas diagnosed, thus ophthalmological examination on
a regular basis should be considered. Because of an increased
incidence of cardiac defects, echocardiography should be
performed in all patients and followed up accordingly. Several
patients presented with cholelithiasis, thus abdominal ultrasound
should be performed in cases of unexplained pain (colic).
Biochemically, assays of protein status, plasma amino acids,
tHcy, AdoMet, AdoHcy, adenosine in urine and/or dried blood
spot, serum aminotransferases, total and direct bilirubin, ammo-
nia, blood glucose, uric acid, coagulation tests and alfa-feto pro-
tein are relevant. Regular blood glucose profiles should be per-
formed, depending on the presence and treatment of recurrent
hypoglycaemia. A complete blood count should be included in
the regular monitoring to check for megaloblastic anemia.
Statement #31. Grade of recommendation C-D
Close clinical and biochemical monitoring is needed, includ-
ing monitoring of psychomotor development, liver function
and hypoglycaemia.
Complications
Severe neonatal hyperbilirubinemia could lead to kernicterus if
not treated early and aggressively. Hepatopathy can progress to
liver failure and there was one case of hepatorenal syndrome.
Development of a malignant hepatic tumour was observed in
one patient. Recurrent hypoglycaemia, especially during the
neonatal period, may be severe and can lead to further brain
damage. Epilepsy can become very severe and difficult to man-
age. Some patients developed severe behavioural problems.
Discussion
Although there are many specific aspects related to each of the
four methylation disorders discussed in this paper, they also
have some common features and some common recommen-
dations are valid for them.
Regarding recognition and diagnostic work-up, it has to be
taken into account that Bhypermethioninemia^, which is the
biochemical hallmark of this group of diseases, is not always
present in early infancy. Accordingly, newborn screening (in
countries which screen for CBS deficiency) will very likely
miss a large proportion of patients and a high level of awareness
of these disorders is needed to recognize affected patients in this
age group. Accordingly, specific tests (AdoMet, AdoHcy,
tHcy) may be indicated in all sick young infants with unex-
plained signs and symptoms listed above. In summary, this
could be any suspicious finding or combination of unexplained
neurological signs, myopathy, liver disease, dysmorphism as
described in the section for ADK deficiency, unexplained ele-
vation of aminotransferases or CK activity.
In evaluation of liver disease it should be kept in mind that
hypermethioninemia is not always an unspecific secondary find-
ing. Regardless of the current clinical presentation, every case of
hypermethioninemia requires appropriate investigation (see
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Fig. 2), which should not be postponed since early diagnosis can
improve the outcome in those patients who benefit from appro-
priate treatment. Unfortunately, the investigation of the key me-
tabolites AdoMet and AdoHcy is currently performed in very
few specialized metabolic laboratories. AdoMet and AdoHcy
can be measured in plasma. AdoMet is known to be unstable
at normal pH but rather stable under acidic conditions: the rec-
ommendation is to separate plasma as soon as possible (1 ml of
plasma is sufficient). Next add to 10 parts of plasma 1 part of 1N
acetic acid and store at −20 °C (Gellekink et al 2005).2 Because
concentrations of AdoMet and AdoHcy are in the nmol range,
sensitive LC-MS/MS methods have to be employed. Whole
blood analyses can be inaccurate. Homocysteine should bemea-
sured in plasma as tHcy, which is available in most clinical
chemistry laboratories. The assays for amino acids analyses usu-
ally do not detect moderately elevated tHcy.
Considering the complex pathogenesis involving an uncer-
tain number of essential methylation processes, treatment op-
tions for methylation disorders, with the exception ofMAT I/III
deficiency, can hardly be comprehensive. One common aspect
is the lack of evidence that infections, surgery or other short
catabolic periodsmay cause significant problems to the patients
in comparison to healthy children. Accordingly, there is no
evidence in support of a need to avoid catabolic periods or
for specific emergency treatment. Due to the complexity of
treatment and follow-up it is recommended that all patients
with methylation disorders are treated and monitored under
the surveillance of specialized centres. The limited number of
patients renders collaborative studies difficult, but important.
Finally, it should be taken into account that the recommen-
dations provided in this publication are based on general prin-
ciples and only a very limited number of patients and publica-
tions, and in practice should be adjusted individually according
to patient’s age, severity of the disease, and clinical and labo-
ratory findings. Much more experience is necessary to offer
more accurate answers to many remaining questions and un-
certainties of methylation disorders including long-term disease
manifestations and complications. One important tool for
gaining these experiences are registries like the BE-HOD
(European network and registry for homocystinurias and meth-
ylation defects)^ registry (see https://www.ehod-registry.org/
and http://www.e-hod.org/). We would like to encourage all
care-takers to include their patients with methylation disorders
in the BE-HOD^ registry, which would enable the development
of better guidelines of methylation disorders in the future.
Statement #32. Grade of recommendation C-D
According to current knowledge, there is no need for a specific
regimen in catabolic situations for any of the four methylation
disorders.
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